GB/T 16886.11-2021 PDF in English
GB/T 16886.11-2021 (GB/T16886.11-2021, GBT 16886.11-2021, GBT16886.11-2021)
| Standard ID | Contents [version] | USD | STEP2 | [PDF] delivered in | Name of Chinese Standard | Status |
| GB/T 16886.11-2021 | English | 440 |
Add to Cart
|
0-9 seconds. Auto-delivery.
|
Biological evaluation of medical devices -- Part 11: Tests for systemic toxicity
| Valid |
| GB/T 16886.11-2011 | English | 175 |
Add to Cart
|
0-9 seconds. Auto-delivery.
|
Biological evaluation of medical devices -- Part 11: Tests for systemic toxicity
| Obsolete |
| GB/T 16886.11-1997 | English | 559 |
Add to Cart
|
3 days
|
Biological evaluation of medical devices--Part 11: Tests for systemic toxicity
| Obsolete |
Standards related to (historical): GB/T 16886.11-2021
PDF Preview
GB/T 16886.11-2021: PDF in English (GBT 16886.11-2021) GB/T 16886.11-2021
NATIONAL STANDARD OF THE
PEOPLE’S REPUBLIC OF CHINA
ICS 11.100.20
CCS C 30
GB/T 16886.11-2021 / ISO 10993-11:2017
Replacing GB/T 16886.11-2011
Biological evaluation of medical devices -
Part 11: Tests for systemic toxicity
(ISO 10993-11:2017, IDT)
ISSUED ON: NOVEMBER 26, 2021
IMPLEMENTED ON: DECEMBER 01, 2022
Issued by: State Administration for Market Regulation;
Standardization Administration of the PRC.
Table of Contents
Foreword ... 4
Introduction ... 6
1 Scope ... 9
2 Normative references ... 9
3 Terms and definitions ... 9
4 General considerations ... 11
4.1 General ... 11
4.2 Selection of animal species ... 12
4.3 Animal status ... 12
4.4 Animal care and husbandry ... 12
4.5 Size and number of groups ... 13
4.5.1 Size of groups ... 13
4.5.2 Number of groups ... 13
4.5.3 Treatment controls ... 14
4.6 Route of exposure ... 14
4.7 Sample preparation ... 14
4.8 Dosing ... 14
4.8.1 Test sample administration ... 14
4.8.2 Dosage volumes ... 15
4.8.3 Dosage frequency ... 15
4.9 Body weight and food/water consumption ... 16
4.10 Clinical observations ... 16
4.11 Clinical pathology ... 16
4.12 Anatomic pathology ... 17
4.13 Study designs ... 17
4.14 Quality of investigation ... 17
5 Acute systemic toxicity ... 18
5.1 General ... 18
5.2 Study design ... 18
5.2.1 Preparations ... 18
5.2.2 Experimental animals ... 18
5.2.3 Test conditions ... 19
5.2.4 Body weights ... 19
5.2.5 Clinical observations ... 19
5.2.6 Pathology ... 20
5.3 Evaluation criteria ... 21
5.3.1 General ... 21
5.3.2 Evaluation of results ... 21
5.4 Final report ... 22
6 Repeated exposure systemic toxicity (subacute, subchronic and chronic systemic
toxicity) ... 23
6.1 General ... 23
6.2 Study design ... 24
6.2.1 Preparations ... 24
6.2.2 Experimental animals ... 24
6.2.3 Test conditions ... 25
6.2.4 Body weights ... 25
6.2.5 Clinical observations ... 25
6.2.6 Pathology ... 26
6.3 Evaluation criteria ... 27
6.3.1 General ... 27
6.3.2 Evaluation of results ... 27
6.4 Final report ... 28
Annex A (Informative) Routes of administration ... 29
Annex B (Informative) Dosage volumes ... 32
Annex C (Informative) Common clinical signs and observations ... 33
Annex D (Informative) Suggested haematology, clinical chemistry and urinalysis
measurements ... 34
Annex E (Informative) Suggested organ list for histopathological evaluation ... 36
Annex F (Informative) Organ list for limited histopathology for medical devices
subjected to systemic toxicity testing ... 39
Annex G (Informative) Information on material-mediated pyrogens ... 41
Annex H (Informative) Subchronic rat systemic toxicity - Dual routes of parenteral
administration... 43
Bibliography ... 45
Foreword
This document is drafted in accordance with GB/T 1.1-2020 "Directives for
standardization - Part 1: Rules for the structure and drafting of standardizing
documents".
The document is Part 11 of GB/T 16886 "Biological evaluation of medical devices".
GB/T 16886 has issued the following parts:
- Part 1: Evaluation and testing within a risk management process;
- Part 2: Animal welfare requirements;
- Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity;
- Part 4: Selection of tests for interactions with blood;
- Part 5: Tests for in vitro cytotoxicity;
- Part 6: Tests for local effects after implantation;
- Part 7: Ethylene oxide sterilization residuals;
- Part 9: Framework for identification and quantification of potential degradation
products;
- Part 10: Tests for irritation and skin sensitization;
- Part 11: Tests for systemic toxicity;
- Part 12: Sample preparation and reference materials;
- Part 13: Identification and quantification of degradation products from polymeric
medical devices;
- Part 14: Identification and quantification of degradation products from ceramics;
- Part 15: Identification and quantification of degradation products from metals and
alloys;
- Part 16: Toxicokinetic study design for degradation products and leachables;
- Part 17: Establishment of allowable limits for leachable substances;
- Part 18: Chemical characterization of materials;
- Part 19: Physico-chemical, morphological and topographical characterization of
materials;
- Part 20: Principles and methods for immunotoxicology testing of medical devices.
This document replaces GB/T 16886.11-2011 "Biological evaluation of medical
devices - Part 11: Tests for systemic toxicity". Compared with GB/T 16886.11-2011,
the main technical change is as follows:
- Modify the size of groups for chronic toxicity tests (see Table 1; Table 1 of the
2011 edition).
This document, using translation method, is identical to ISO 10993-11:2017
"Biological evaluation of medical devices - Part 11: Tests for systemic toxicity".
China’s documents which have a consistent correspondence with the international
documents normatively referenced in this document are as follows:
- GB/T 16886.1-2011 Biological evaluation of medical devices - Part 1: Evaluation
and testing within a risk management process (ISO 10993-1:2009, IDT);
- GB/T 16886.2-2011 Biological evaluation of medical devices - Part 2: Animal
welfare requirements (ISO 10993-2:2006, IDT).
Attention is drawn to the possibility that some of the elements of this document may be
the subject of patent rights. The issuing authority of this document shall not be held
responsible for identifying any or all such patent rights.
This document was proposed by National Medical Products Administration.
This document shall be under the jurisdiction of National Technical Committee 248 on
Biological Evaluation of Medical Devices of Standardization Administration of China
(SAC/TC 248).
Drafting organizations of this document: Shandong Quality Inspection Center for
Medical Devices, National Institutes for Food and Drug Control.
Main drafters of this document: Wang Xin, Sun Likui, Han Qianqian, Wang Han, Chu
Xiangyu, Xu Jing.
The previous releases of this document and the documents it replaces are as follows:
- It was first issued in 1997 as GB/T 16886.11-1997 and first revised in 2011;
- This is the second revision.
Biological evaluation of medical devices -
Part 11: Tests for systemic toxicity
1 Scope
This document specifies requirements and gives guidance on procedures to be followed
in the evaluation of the potential for medical device materials to cause adverse systemic
reactions.
This document applies to systemic toxicity studies of medical devices or materials.
2 Normative references
The contents of the following documents, through normative references in this text,
constitute indispensable provisions of this document. Among them, for dated references,
only the edition corresponding to that date applies to this document. For undated
references, the latest edition (including all amendments) applies to this document.
ISO 10993-1 Biological evaluation of medical devices - Part 1: Evaluation and
testing within a risk management process
ISO 10993-2 Biological evaluation of medical devices - Part 2: Animal welfare
requirements
3 Terms and definitions
For the purposes of this document, the terms and definitions given in ISO 10993-1 and
the following apply.
3.1
Dose/dosage
Amount of test sample administered (e.g. mass, volume) expressed per unit of body
weight or surface area.
3.2
Dose-effect
Relationship between the dosage and the magnitude of a defined biological effect either
in an individual or in a population sample.
......
Source: Above contents are excerpted from the PDF -- translated/reviewed by: www.chinesestandard.net / Wayne Zheng et al.
|